Recap: Century Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Century Therapeutics (NASDAQ:IPSC) reported Q3 earnings, missing estimated earnings by 7.84% with an EPS of $-0.55 versus an estimate of $-0.51. Revenue was down $2.08 million from the same period last year. Last quarter, the company also missed on EPS by $0.02, which was followed by a 4.91% drop in the share price the next day.
November 09, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Century Therapeutics' Q3 earnings missed estimates and revenue was down YoY. Similar performance last quarter led to a share price drop.
Century Therapeutics reported lower than expected earnings and a decrease in revenue. This negative financial performance is likely to impact investor sentiment and could lead to a decrease in the company's share price, as was the case in the previous quarter when the company also missed earnings estimates.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100